Cardiol Therapeutics (CRDL) Stock Price, Quote & News

Company Profile

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutan...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 289 910 0850

Fax: 905 481 2394

Website: www.cardiolrx.com

Address:

2265 Upper Middle Road East, Suite 602, Oakville, Canada

PDM21 May. 26 at 7:35 PM

$CRDL anyone else think it’s possible that Tim Garnett has withheld from buying and the company has yet to offer him stock options or equities is by design due to avoiding insider trading and investor scrutiny? If they are currently involved in any deal I’d bet everything he’s the one doing the brokering. I’ve been wanting to see him acquiring or see what the company is going to offer him. I feel like if he’s refraining and the company doesn’t announce his share package at the investor meeting that could be a solid sign something is actually about to happen

1 · Reply

Covode13 May. 26 at 3:27 PM

$CRDL

0 · Reply

mmtiddy May. 26 at 9:49 AM

$CRDL What’s the vote for, I can’t even log in

1 · Reply

PDM21 May. 23 at 1:55 PM

$CRDL investors annual meeting is several weeks later this year. I’m wondering if they are anticipating completion of enrollment of maverick by then and/or there’s a reason why it’s later this year.

1 · Reply

Covode13 May. 22 at 1:45 PM

$CRDL let’s start conversations. Best partner for CRDL and why? Companies that would want to partner and why?

2 · Reply

BearButcher May. 21 at 10:57 PM

$CRDL LONG 🏹🌟

0 · Reply

Covode13 May. 21 at 10:45 AM

$CRDL

0 · Reply

Outcomes May. 19 at 11:51 PM

$GTBP $IBRX $CRDL ....saw a TV ad for GTBP and decided to take a look 🤔🤣

0 · Reply

PDM21 May. 19 at 6:12 PM

$CRDL any listen to the meeting? Did it cut off for you half way through?

2 · Reply

Covode13 May. 19 at 2:37 PM

$CRDL

0 · Reply

Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ

May 11, 2026, 4:00 PM EDT - 15 days ago

Cardiol Therapeutics Registration statement: Q1 2026

May 11, 2026, 4:00 PM EDT - 15 days ago

Cardiol Therapeutics Registration statement: Q1 2026

May 8, 2026, 7:00 AM EDT - 19 days ago

Cardiol Therapeutics Slides: Corporate presentation

Thu, 07 May 2026 07:27:00 -0400 - 20 days ago

Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association

2026-04-28T13:37:09.000Z - 4 weeks ago

Cardiol Therapeutics (CRDL) Expands MAVERIC Trial with New Clinical Sites

2026-04-28T12:12:25.000Z - 4 weeks ago

Cardiol Therapeutics expands U.S. MAVERIC Phase III trial network

Tue, 28 Apr 2026 07:27:00 -0400 - 4 weeks ago

Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

Apr 14, 2026, 12:00 PM EDT - 6 weeks ago

Cardiol Therapeutics Transcript: Study result

Tue, 14 Apr 2026 07:27:00 -0400 - 6 weeks ago

Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart

2026-04-06T16:33:41.000Z - 7 weeks ago

Cardiol Therapeutics (CRDL) Receives 'Buy' Rating from Canaccord Genuity | CRDL Stock News

Apr 2, 2026, 7:00 AM EDT - 7 weeks ago

Cardiol Therapeutics Slides: Corporate presentation

Wed, 01 Apr 2026 07:27:00 -0400 - 2 months ago

Cardiol Therapeutics Announces Year-End 2025 Update on Operations

Mar 31, 2026, 7:00 AM EDT - 2 months ago

Cardiol Therapeutics Annual report: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 2 months ago

Cardiol Therapeutics Registration statement: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 2 months ago

Cardiol Therapeutics Registration statement: Q4 2025

2026-03-04T21:00:29.000Z - 2 months ago

Cardiol Therapeutics Inc at TD Cowen Healthcare Conference Transcript

Mar 4, 2026, 10:30 AM EST - 3 months ago

Cardiol Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Wed, 25 Feb 2026 07:27:00 -0500 - 3 months ago

Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference

Tue, 10 Feb 2026 07:27:00 -0500 - 3 months ago

Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure

Fri, 23 Jan 2026 09:16:00 -0500 - 4 months ago

Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million

2026-01-16T14:00:15.000Z - 4 months ago

Cardiol Therapeutics trading resumes

Fri, 16 Jan 2026 08:46:00 -0500 - 4 months ago

Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

Fri, 16 Jan 2026 08:42:00 -0500 - 4 months ago

Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

2026-01-16T13:16:37.000Z - 4 months ago

Cardiol Therapeutics trading halted, news pending

Tue, 13 Jan 2026 07:27:00 -0500 - 4 months ago

Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

2025-12-17T13:38:24.000Z - 5 months ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research... • news

Dec 3, 2025, 7:00 AM EST - 6 months ago

Cardiol Therapeutics Slides: Corporate Presentation

2025-12-02T21:22:00.000Z - 6 months ago

Cardiol Therapeutics Inc To Present Phase II ARCHER Results Transcript

2025-12-01T18:31:54.000Z - 6 months ago

Cardiol Therapeutics (CRDL): HC Wainwright & Co. Reiterates Buy Rating | CRDL Stock News

Dec 1, 2025, 8:30 AM EST - 6 months ago

Cardiol Therapeutics Transcript: Study Result

Dec 1, 2025, 8:30 AM EST - 6 months ago

Cardiol Therapeutics Press release: Study Result

Mon, 01 Dec 2025 07:27:00 -0500 - 6 months ago

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

Thu, 13 Nov 2025 07:45:00 -0500 - 6 months ago

Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040

Nov 12, 2025, 6:00 PM EST - 6 months ago

Cardiol Therapeutics Registration statement: Q3 2025

Nov 12, 2025, 6:00 PM EST - 6 months ago

Cardiol Therapeutics Registration statement: Q3 2025

Nov 5, 2025, 7:45 AM EST - 7 months ago

Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

Nov 5, 2025, 7:00 AM EST - 7 months ago

Cardiol Therapeutics Registration statement: Registration Filing

Oct 21, 2025, 7:27 AM EDT - 7 months ago

Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027

2025-10-17T21:05:14.000Z - 7 months ago

Cardiol Therapeutics trading resumes

Oct 17, 2025, 4:34 PM EDT - 7 months ago

Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027

2025-10-17T20:15:13.000Z - 7 months ago

Cardiol Therapeutics trading halted, news pending

Aug 14, 2025, 4:00 PM EDT - 10 months ago

Cardiol Therapeutics Registration statement: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 10 months ago

Cardiol Therapeutics Registration statement: Q2 2025

Aug 12, 2025, 9:30 AM EDT - 10 months ago

Cardiol Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 11, 2025, 7:27 AM EDT - 10 months ago

Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference

2025-08-06T15:50:41.000Z - 10 months ago

Roth bullish on Cardiol, says trial results enough to attract larger partner

2025-08-06T14:10:29.000Z - 10 months ago

Cardiol ARCHER study not statistically significant, says Canaccord

2025-08-06T13:10:23.000Z - 10 months ago

Cardiol Therapeutics announces Phase II ARCHER results in myocarditis

Aug 6, 2025, 7:27 AM EDT - 10 months ago

Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

Jul 22, 2025, 7:27 AM EDT - 11 months ago

Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

Jun 9, 2025, 5:02 PM EDT - 1 year ago

Cardiol Therapeutics Slides: Corporate Presentation

2025-06-02T10:10:15.000Z - 1 year ago

Cardiol Therapeutics initiated with a Buy at H.C. Wainwright

May 29, 2025, 7:27 AM EDT - 1 year ago

Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders

May 27, 2025, 7:27 AM EDT - 1 year ago

Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT

May 13, 2025, 6:00 PM EDT - 1 year ago

Cardiol Therapeutics Registration statement: Q1 2025

May 13, 2025, 6:00 PM EDT - 1 year ago

Cardiol Therapeutics Registration statement: Q1 2025

Apr 29, 2025, 7:27 AM EDT - 1 year ago

Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors

Apr 16, 2025, 7:27 AM EDT - 1 year ago

Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

2025-04-02T19:05:59.000Z - 1 year ago

Cardiol Therapeutics management to meet with Oppenheimer

Apr 1, 2025, 4:00 PM EDT - 1 year ago

Cardiol Therapeutics Registration statement: Q4 2024

Apr 1, 2025, 4:00 PM EDT - 1 year ago

Cardiol Therapeutics Registration statement: Q4 2024

Apr 1, 2025, 7:27 AM EDT - 1 year ago

Cardiol Therapeutics Announces Year-End 2024 Update on Operations

Mar 5, 2025, 11:10 AM EST - 1 year ago

Cardiol Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 7:27 AM EST - 1 year ago

Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Feb 20, 2025, 7:27 AM EST - 1 year ago

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure

Feb 11, 2025, 4:00 PM EST - 1 year ago

Cardiol Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 4, 2025, 7:27 AM EST - 1 year ago

Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

2025-01-28T12:01:58.000Z - 1 year ago

Cardiol Therapeutics initiated with a Buy at Rodman & Renshaw

Dec 19, 2024, 8:30 AM EST - 1 year ago

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

Dec 18, 2024, 10:00 AM EST - 1 year ago

Cardiol Therapeutics Slides: Corporate Presentation

Nov 29, 2024, 8:02 AM EST - 1 year ago

3 Penny Stocks Ready to Break Out in 2025

GOVX VUZI

Nov 18, 2024, 11:37 AM EST - 1 year ago

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Nov 14, 2024, 10:30 AM EST - 1 year ago

Cardiol Therapeutics Registration statement: Q3 2024

Nov 14, 2024, 10:30 AM EST - 1 year ago

Cardiol Therapeutics Registration statement: Q3 2024

2024-11-13T13:26:13.000Z - 1 year ago

Cardiol Therapeutics added to PRISM Emerging Biotech Index

Nov 13, 2024, 8:00 AM EST - 1 year ago

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

Oct 22, 2024, 6:30 AM EDT - 1 year ago

Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis

Oct 11, 2024, 8:39 AM EDT - 1 year ago

Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option

Oct 10, 2024, 9:09 AM EDT - 1 year ago

Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares

2024-10-09T13:50:57.000Z - 1 year ago

Cardiol Therapeutics 8.44M share Secondary priced at $1.60

Oct 9, 2024, 7:58 AM EDT - 1 year ago

Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

Oct 8, 2024, 4:01 PM EDT - 1 year ago

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

Sep 24, 2024, 7:27 AM EDT - 1 year ago

Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis

Sep 10, 2024, 7:27 AM EDT - 1 year ago

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

Aug 12, 2024, 10:45 AM EDT - 1 year ago

Cardiol Therapeutics Registration statement: Q2 2024

Aug 12, 2024, 10:45 AM EDT - 1 year ago

Cardiol Therapeutics Registration statement: Q2 2024

Jul 18, 2024, 7:00 AM EDT - 2 years ago

Cardiol Therapeutics Slides: Corporate presentation

Jul 12, 2024, 8:00 AM EDT - 2 years ago

Cardiol Therapeutics Registration statement: Registration Filing

Jul 5, 2024, 8:00 AM EDT - 2 years ago

Cardiol Therapeutics Registration statement: Registration Filing

Jun 27, 2024, 12:29 PM EDT - 2 years ago

Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

2024-06-26T11:53:03.000Z - 2 years ago

Cardiol Therapeutics initiated with a Buy at Roth MKM

2024-06-26T08:52:24.000Z - 2 years ago

Cardiol Therapeutics initiated with a Buy at B. Riley

Jun 25, 2024, 7:27 AM EDT - 2 years ago

Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT

2024-06-13T18:40:24.000Z - 2 years ago

Cardiol Therapeutics shares fall after primary endpoint data from MAvERIC-Pilot

Jun 13, 2024, 7:58 AM EDT - 2 years ago

Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

2024-05-23T11:00:21.000Z - 2 years ago

Cardiol Therapeutics price target raised to $8 from $6 at Canaccord

May 14, 2024, 11:00 AM EDT - 2 years ago

Cardiol Therapeutics Registration statement: Q1 2024

May 14, 2024, 11:00 AM EDT - 2 years ago

Cardiol Therapeutics Registration statement: Q1 2024

May 14, 2024, 7:27 AM EDT - 2 years ago

Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024

Apr 2, 2024, 6:00 AM EDT - 2 years ago

Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Apr 1, 2024, 12:40 PM EDT - 2 years ago

Cardiol Therapeutics Annual report: Q4 2023

Apr 1, 2024, 12:40 PM EDT - 2 years ago

Cardiol Therapeutics Registration statement: Q4 2023

Apr 1, 2024, 12:40 PM EDT - 2 years ago

Cardiol Therapeutics Registration statement: Q4 2023

Feb 21, 2024, 7:27 AM EST - 2 years ago

Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Feb 15, 2024, 7:27 AM EST - 2 years ago

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Jan 24, 2024, 7:27 AM EST - 2 years ago

Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market

Jan 9, 2024, 7:27 AM EST - 2 years ago

Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis

Dec 5, 2023, 7:27 AM EST - 2 years ago

Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot

Nov 16, 2023, 5:30 AM EST - 2 years ago

Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Nov 14, 2023, 10:30 AM EST - 2 years ago

Cardiol Therapeutics Registration statement: Q3 2023

Nov 14, 2023, 10:30 AM EST - 2 years ago

Cardiol Therapeutics Registration statement: Q3 2023

Nov 1, 2023, 7:27 AM EDT - 2 years ago

Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis

PDM21 May. 26 at 7:35 PM

1 · Reply

Covode13 May. 26 at 3:27 PM

$CRDL

0 · Reply

mmtiddy May. 26 at 9:49 AM

$CRDL What’s the vote for, I can’t even log in

1 · Reply

PDM21 May. 23 at 1:55 PM

1 · Reply

Covode13 May. 22 at 1:45 PM

$CRDL let’s start conversations. Best partner for CRDL and why? Companies that would want to partner and why?

2 · Reply

BearButcher May. 21 at 10:57 PM

$CRDL LONG 🏹🌟

0 · Reply

Covode13 May. 21 at 10:45 AM

$CRDL

0 · Reply

Outcomes May. 19 at 11:51 PM

$GTBP $IBRX $CRDL ....saw a TV ad for GTBP and decided to take a look 🤔🤣

0 · Reply

PDM21 May. 19 at 6:12 PM

$CRDL any listen to the meeting? Did it cut off for you half way through?

2 · Reply

Covode13 May. 19 at 2:37 PM

$CRDL

0 · Reply

ElieoG May. 18 at 8:25 PM

$CRDL potential partners are definatly waiting for the final results. No one in there righ minds would take a risk and partner with something that isnt 95% done. Its a matter fot time, all the data suggest the company will receive an approval por the Maverick Trial. I couldnt care less about one last private funding , wich is a normal process for any bio tech stock. It almost has 0 impact on the SP that is allready undervalued.

1 · Reply

Covode13 May. 18 at 4:53 PM

$CRDL Wow we fall again

2 · Reply

NancyPelosi____insider May. 18 at 3:46 PM

$CRDL :/

0 · Reply

Covode13 May. 18 at 12:11 PM

$CRDL 💩

0 · Reply

fitz0228 May. 17 at 11:05 AM

$CRDL Look at new ownership. Mmcap. Look for new releases regarding this.

1 · Reply

PDM21 May. 16 at 10:56 PM

$CRDL J.P. Morgan bought in 50k. Not a huge statement but still a statement. Citadel owns 800k. If they hold that’s bullish.

0 · Reply

PDM21 May. 16 at 10:52 PM

$CRDL institutional ownership is nearly 30m. We were under 10m forever. I’ll be interested to see if MMcap sold any during this pullback.

0 · Reply

Livingdreams May. 15 at 8:42 AM

$CRDL tipranks shows may 19th.

0 · Reply

HeyYio May. 14 at 9:59 PM

$CRDL I am feeling really good about CRDL. Can't explain it fully. More gut than anything. I just feel we have a winner winner chicken dinner on the table here. I am feeling good about 5-7 bucks when results are out and we to go to new drug application. Fingers crossed..

1 · Reply

TheWinningStock May. 14 at 9:34 PM

$GTBP <<--This is 💩💩💩👎 $IBRX <<--- The real deal 🤑🚀 $CRDL <<--- another winner 🤑

0 · Reply

NancyPelosi____insider May. 14 at 12:18 PM

$CRDL no blazingstocks is encouraging

0 · Reply

Covode13 May. 14 at 12:00 PM

$CRDL

0 · Reply

Market Cap	147.60M
Revenue (ttm)	0.00
Net Income (ttm)	-24.20M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	330,500
Avg Vol	763,206
Day's Range	N/A - N/A
Shares Out	111.82M
Stochastic %K	33%
Beta	0.77
Analysts	Strong Sell
Price Target	$6.74